Provided by Tiger Trade Technology Pte. Ltd.

Minerva Neurosciences

7.30
-0.6400-8.06%
Post-market: 7.24-0.0564-0.77%19:55 EDT
Volume:222.28K
Turnover:1.69M
Market Cap:315.90M
PE:-3.94
High:7.86
Open:7.65
Low:7.26
Close:7.94
52wk High:12.46
52wk Low:1.15
Shares:43.27M
Float Shares:5.44M
Volume Ratio:0.64
T/O Rate:4.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8533
EPS(LYR):0.1901
ROE:-675.09%
ROA:-25.82%
PB:-9.14
PE(LYR):38.40

Loading ...

Minerva Neurosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Nov 15, 2025

Minerva Neurosciences Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 11, 2025

Minerva Neurosciences (NERV) Gets a Hold from H.C. Wainwright

TIPRANKS
·
Nov 10, 2025

Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Nov 06, 2025

Minerva price target lowered to $4 from $5 at H.C. Wainwright

TIPRANKS
·
Nov 06, 2025

Minerva Neurosciences reports $2.7 mln Q3 net loss

Reuters
·
Nov 05, 2025

Minerva Neurosciences Q3 EPS $(0.36) Misses $(0.35) Estimate

Benzinga
·
Nov 05, 2025

BRIEF-Minerva Neurosciences Q3 Net Income USD -2.744 Million

Reuters
·
Nov 05, 2025

Minerva Neurosciences Secures $80 Million Financing and Plans Phase 3 Roluperidone Trial

Reuters
·
Nov 05, 2025

Minerva Neurosciences Q3 Operating Expenses USD 2.844 Million

THOMSON REUTERS
·
Nov 05, 2025

Minerva Neurosciences Inc: on a Path Forward to Advancing Roluperidone for Treatment of Negative Symptoms of Schizophrenia

THOMSON REUTERS
·
Nov 05, 2025

Minerva Neurosciences: R&D,Admin Costs May Rise, but We’re Well Positioned to Fund Phase 3, Nda Resubmission and Launch Prep for Roluperidone in US

THOMSON REUTERS
·
Nov 05, 2025

Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial

Dow Jones
·
Oct 21, 2025

Shares of Minerva Neurosciences More Than Double After Co Secures up to $200 Million in Private Placement, Last up 163.2%

THOMSON REUTERS
·
Oct 21, 2025

Why Is Minerva Neurosciences Stock (NERV) Up 165% Today?

TIPRANKS
·
Oct 21, 2025

BRIEF-Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

Reuters
·
Oct 21, 2025

Minerva Neurosciences - Expected to Be Sufficiently Funded Through Confirmatory Phase 3 Trial for Roluperidone & Resubmission of Nda to FDA

THOMSON REUTERS
·
Oct 21, 2025

Minerva Neurosciences Inc - Will Increase Size of Its Board of Directors and Will Appoint up to Three Directors

THOMSON REUTERS
·
Oct 21, 2025

Minerva Neurosciences- Further $40 Mln Proceeds May Be Received Connected With Cash Exercise of Tranche B Warrants Contingent on Reaching Milestone

THOMSON REUTERS
·
Oct 21, 2025